This is a securities regulator's record of an organisation that files with it, not a company register filing. Its company register holds its legal status.
Business address
983 UNIVERSITY AVENUE, BLDG. B
95032 LOS GATOS
CA
United States
Other identifiers
- EIN320074500
Filing details
- SIC code
- 2834
- Register
- SEC EDGAR
- Annual figures (XBRL)
- Assets: USD 14,695,000 at 2022-12-31 (10-K, filed 2023-05-22), Equity: USD -24,232,000 at 2022-12-31 (10-K, filed 2023-05-22), Revenue: USD 3,091,000 for the year to 2022-12-31 (10-K, filed 2023-05-22), Net income: USD -30,371,000 for the year to 2022-12-31 (10-K, filed 2023-05-22), Liabilities: USD 38,927,000 at 2022-12-31 (10-K, filed 2023-05-22), Public float: USD 12,200,000 at 2022-06-30 (10-K, filed 2023-05-22), Shares outstanding: 44,574,021 shares at 2023-09-30 (10-Q, filed 2023-11-06)
- Filer category
- Emerging growth company
- Fiscal year end
- 31 December
- Industry (SIC)
- Pharmaceutical Preparations
- Latest filing date
- 2026-08-14
- Latest filing form
- SCHEDULE 13G/A
- State of incorporation code
- DE
- State or country of incorporation
- DE
Not supplied by the register: EDGAR bulk file date.
History
Versions of this record since CorporateDB began collecting it.
- 12 Nov 2026Version 2
Aridis Pharmaceuticals, Inc. · No status published
- 10 Nov 2026Version 1
Aridis Pharmaceuticals, Inc. · No status published
Source and reuse
U.S. Securities and Exchange Commission, EDGAR
Source: U.S. Securities and Exchange Commission, EDGAR bulk submissions and XBRL company facts; filtered and reformatted by CorporateDB.
- Licence
- Public domain: a work of the United States Government (17 U.S.C. 105) ↗ Terms of use ↗ Source ↗
- Changes
- Data filtered and reformatted by CorporateDB.